PTC Therapeutics, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: PTC Therapeutics or Veracyte?

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, PTC Therapeutics, Inc. and Veracyte, Inc. have shown distinct strategies in handling these costs. PTC Therapeutics has seen a consistent rise in SG&A expenses, peaking at approximately $332 million in 2023, reflecting a growth of over 640% from 2014. In contrast, Veracyte's SG&A expenses increased by about 350% during the same period, reaching around $184 million in 2023. This suggests that while both companies are expanding, PTC Therapeutics is investing more aggressively in its administrative and sales functions. Investors and stakeholders should consider these trends when evaluating the companies' operational efficiencies and strategic priorities. Understanding these dynamics can provide insights into each company's growth trajectory and market positioning.